Company intelligence / Profile preview
Strand Therapeutics
Boston, Massachusetts, United Statesstrandtx.com ↗
- Ownership
- Private
- Employees
- ~99
- Development stage
- Phase 1
01
Overview
Strand Therapeutics has received IND clearance for its programmable mRNA therapy STX-001 to treat solid tumors. The company has presented preclinical data on STX-001 at AACR 2023.
- Therapeutic areas
- OncologyHematology
- Modalities
- mRNA therapeuticsprogrammable mRNAself-replicating mRNAs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
BeiGene (partnership to develop and commercialize multi-functional mRNA treatments for solid tumors)
Beyond the preview
Go deeper on Strand Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Strand Therapeutics.